Evidence map›Paper›PMID 37652506›Full record

ArticleIn vivo (Athens, Greece)

Durable Stable Disease by Atezolizumab/Bevacizumab Can Provide Long-term Survival of Patients With Hepatocellular Carcinoma Lung Metastases.

Toshihiko Motohara, Kensuke Yamamura, Hideaki Miyamoto, Shigenori Ueno, Hiroshi Takeno, Yasunori Nagayama, Eri Oda, Ryuichi Karashima, Nobuyuki Ozaki, Tatsunori Miyata and 4 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Toshihiko MotoharaDepartment of Gastroenterology, Yamaga City Medical Center, Kumamoto, Japan.
Kensuke YamamuraDepartment of Surgery, Yamaga City Medical Center, Kumamoto, Japan.
Hideaki MiyamotoDepartment of Medical Oncology, Yamaga City Medical Center, Kumamoto, Japan.
Shigenori UenoDepartment of Gastroenterology, Yamaga City Medical Center, Kumamoto, Japan.
Hiroshi TakenoDepartment of Gastroenterology, Yamaga City Medical Center, Kumamoto, Japan.
Yasunori NagayamaDepartment of Diagnostic Radiology, Graduate School of Life Science, Kumamoto University, Kumamoto, Japan.
Eri OdaDepartment of Surgery, Yamaga City Medical Center, Kumamoto, Japan.
Ryuichi KarashimaDepartment of Surgery, Yamaga City Medical Center, Kumamoto, Japan.
Nobuyuki OzakiDepartment of Surgery, Yamaga City Medical Center, Kumamoto, Japan.
Tatsunori MiyataDepartment of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, Kumamoto, Japan.
Kosuke MimaDepartment of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, Kumamoto, Japan.
Hirohisa OkabeDepartment of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, Kumamoto, Japan.
Takatoshi IsikoDepartment of Surgery, Yamaga City Medical Center, Kumamoto, Japan.
Toru BeppuDepartment of Surgery, Yamaga City Medical Center, Kumamoto, Japan; tbeppu@yamaga-mc.jp.
Kumamoto University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMultiple bilateral lung metastases secondary to hepatocellular carcinoma (HCC) are mainly treated with molecular therapy. Atezolizumab plus bevacizumab can provide excellent long-term survival for patients with a good response. CASE REPORT: A 67-year-old woman underwent right hepatectomy for a primary solitary HCC, 11 cm in diameter, after portal embolization. After 2 years, she developed bilateral lung metastases with >100 nodules, <1 cm in size. She had no viral hepatitis or liver cirrhosis, and the Child-Pugh Grade was A (5 points). Lenvatinib (12 mg daily) was administered as a first-line treatment and continued for 18 months. The best response was stable disease (SD). Subsequently, intravenous atezolizumab (1,200 mg) plus bevacizumab (15 mg/kg) was administered once every three weeks. The best response was SD, which continued for 26 months. After that, cabozantinib treatment was initiated and discontinued after one cycle. Subsequently, dual immune checkpoint inhibitor treatment (durvalumab + tremelimumab) was administered. She has had multiple, but lung-only, metastases over four years. She has been well as an outpatient with the Child-Pugh Grade of A and a performance status of 0.

conclusionEven if atezolizumab plus bevacizumab does not induce a good response, a durable SD could prolong survival in patients with metastatic HCC while maintaining liver function and a good quality-of-life.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsLung NeoplasmsAgedAntibodies, Monoclonal, HumanizedBevacizumabFemaleHumansAntibodies, Monoclonal, HumanizedatezolizumabBevacizumabAtezolizumab plus bevacizumabdurable stable diseasehepatocellular carcinomalung metastasesmolecular therapy

Identifiers

PMID37652506
PMCPMC10500536
OpenAlexW4386337512

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.